不受原中国总裁被拘影响 阿斯利康投资25亿美元在北京新建研发中心

联合早报
22 Mar

阿斯利康英国总部去年11月在投资者交流会上透露,对中国区高管的调查,主要针对抗癌药物从香港到中国大陆的非法进口和销售。 不受原中国区总裁王磊被拘影响,英国制药巨企阿斯利康响应北京市长殷勇号召,投资25亿美元(33亿新元)在中国首都新建在华第二个全球战略研发中心。 与此同时,阿斯利康还签署了两项合作与授权协议,包括与和铂医药达成多特异性抗体疗法的研发合作,以及与元思生肽达成大环肽类药物的开发合作。...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10